Qalsody 100 MG/15 ML vial 15ML
Ended Awarded
- Contract number
- SPE2DR26FMDV5
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $10,989
Award facts
- Contract value 100% obligated
- $10,989.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency (DLA) awarded a delivery order valued at $10,989 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Qalsody 100 mg/15 ml vials. The contract is firm fixed-price with no set-aside designation and carries an ultimate completion date of November 26, 2025. This delivery order was issued under DMS Pharmaceutical Group's broader Indefinite Delivery Contract (IDC) established through the DLA's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion acquisition strategy designed to ensure reliable pharmaceutical supply to Department of Defense healthcare facilities worldwide.
DMS Pharmaceutical Group, registered in the System for Award Management since 2001, has demonstrated substantial federal contracting capability through numerous delivery orders from the DLA's Medical Supply Chain division. The company supplies a comprehensive portfolio of pharmaceutical products spanning branded and generic prescription medications, biologics, vaccines, specialty pharmaceuticals, and medical consumables to support military healthcare operations. Under the PPV-G GEN V contract structure—which features a $499,999,999 ceiling value, a 30-month base period, and three 30-month option periods extending through December 31, 2036—DMS Pharmaceutical Group serves as a critical regional prime vendor contractor positioned to fulfill the diverse pharmaceutical requirements of the Department of Defense's global medical system.
Quick answers
Who was awarded contract SPE2DR26FMDV5?
SPE2DR26FMDV5 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on November 4, 2025.
How much is contract SPE2DR26FMDV5 worth?
The government has obligated $10,989 on SPE2DR26FMDV5.
Is contract SPE2DR26FMDV5 an order under another contract?
Yes. SPE2DR26FMDV5 is a delivery order under SPE2DR25D9114, an indefinite delivery contract.
Was contract SPE2DR26FMDV5 competed?
The extent of competition for SPE2DR26FMDV5 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award